Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight.
about
Tesaglitazar, a dual PPAR{alpha}/{gamma} agonist, ameliorates glucose and lipid intolerance in obese Zucker ratsFenofibrate prevents and reduces body weight gain and adiposity in diet-induced obese rats.Adipocyte fatty acid-binding protein, aP2, alters late atherosclerotic lesion formation in severe hypercholesterolemiaFenofibrate Reduces Age-related Hypercholesterolemia in Normal Rats on a Standard DietRosiglitazone and fenofibrate improve insulin sensitivity of pre-diabetic OLETF rats by reducing malonyl-CoA levels in the liver and skeletal musclePPARα in Obesity: Sex Difference and Estrogen Involvement.Enhancing insulin action: from chemical elements to thiazolidinediones.ABCD2 alters peroxisome proliferator-activated receptor α signaling in vitro, but does not impair responses to fenofibrate therapy in a mouse model of diet-induced obesityA newly identified CG301269 improves lipid and glucose metabolism without body weight gain through activation of peroxisome proliferator-activated receptor alpha and gamma.Different adipose depots: their role in the development of metabolic syndrome and mitochondrial response to hypolipidemic agents.Effects of Bofu-Tsusho-San on diabetes and hyperlipidemia associated with AMP-activated protein kinase and glucose transporter 4 in high-fat-fed miceFish oil and the pan-PPAR agonist tetradecylthioacetic acid affect the amino acid and carnitine metabolism in rats.Update on Safety Issues Related to Antihyperglycemic TherapyElectroacupuncture Reduces Weight Gain Induced by Rosiglitazone through PPARγ and Leptin Receptor in CNSAnti-inflammatory effect of antidiabetic thiazolidinediones prevents bone resorption rather than cartilage changes in experimental polyarthritis.Soluble epoxide hydrolase inhibition and peroxisome proliferator activated receptor γ agonist improve vascular function and decrease renal injury in hypertensive obese rats.Validation of the Antidiabetic and Hypolipidemic Effects of Hawthorn by Assessment of Gluconeogenesis and Lipogenesis Related Genes and AMP-Activated Protein Kinase Phosphorylation.Antiretroviral therapy and the human immunodeficiency virus--improved survival but at what cost?Expression of peroxisome proliferator-activated receptor-gamma in key neuronal subsets regulating glucose metabolism and energy homeostasisPluronic L-81 ameliorates diabetic symptoms in db/db mice through transcriptional regulation of microsomal triglyceride transfer protein.Tesaglitazar, a dual peroxisome proliferator-activated receptor alpha/gamma agonist, reduces atherosclerosis in female low density lipoprotein receptor deficient mice.Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinedionesMaintenance of adiponectin attenuates insulin resistance induced by dietary conjugated linoleic acid in mice.Effect of oxime ether incorporation in acyl indole derivatives on PPAR subtype selectivity.Fenofibrate prevents Rosiglitazone-induced body weight gain in ob/ob mice.A new class of peroxisome proliferator-activated receptor agonists with a novel binding epitope shows antidiabetic effects.Peroxisomal-proliferator-activated receptor alpha activates transcription of the rat hepatic malonyl-CoA decarboxylase gene: a key regulation of malonyl-CoA level.Editor's Highlight: Thy1 (CD90) Expression is Reduced by the Environmental Chemical Tetrabromobisphenol-A to Promote Adipogenesis Through Induction of microRNA-103.Synthesis and anti-diabetic activity of (RS)-2-ethoxy-3-{4-[2-(4-trifluoro-methanesulfonyloxy-phenyl)-ethoxy]-phenyl}-propionic acid.C333H, a novel PPARalpha/gamma dual agonist, has beneficial effects on insulin resistance and lipid metabolism.DRF 2655: a unique molecule that reduces body weight and ameliorates metabolic abnormalities.High content screening for non-classical peroxisome proliferators.The increase in hepatic uncoupling by fenofibrate contributes to a decrease in adipose tissue in obese rats.The peroxisomal proliferator-activated receptor (PPAR) α agonist, fenofibrate, prevents fractionated whole-brain irradiation-induced cognitive impairmentFENOFIBRATE REVERSES CHANGES INDUCED BY HIGH-FAT DIET ON METABOLISM IN MICE MUSCLE AND VISCERAL ADIPOCYTES.Increase in weight induced by muraglitazar, a dual PPARalpha/gamma agonist, in db/db mice: adipogenesis/or oedema?Rosiglitazone attenuates development of polycystic kidney disease and prolongs survival in Han:SPRD rats.Vanadyl acetylacetonate upregulates PPARγ and adiponectin expression in differentiated rat adipocytes.PPARalpha /gamma ragaglitazar eliminates fatty liver and enhances insulin action in fat-fed rats in the absence of hepatomegaly.Combination therapy with PPARgamma and PPARalpha agonists increases glucose-stimulated insulin secretion in db/db mice.
P2860
Q28572510-72997FFA-4C14-4341-B4D4-FA2D21426315Q32065269-F6244608-8A98-4C44-9BC3-F7ACDCDE41CDQ33635141-8CC3BCA7-FBB4-419F-9BF6-8D05B12FD09FQ33849118-30D60DED-461B-458F-8452-78042497976FQ34002703-3EBC1543-0424-44BC-804D-F4C0370C5628Q34143769-13A5BD79-4640-41FE-9344-248A2A501871Q34268346-AA1D9C8B-4C66-4FEA-84BF-AF46F9DDE590Q34360091-774CB0D5-2A91-4CEA-8933-74A6C38B0CF5Q34527082-EC3CBF14-BB09-4DB9-9DAA-56E72208162FQ34591044-3204DDCB-599A-4DD9-B8F3-B76E0106A396Q34685241-2AD57F8E-FC1D-4DF1-8525-23AFABC1EAFAQ34796255-A573FB06-7AD8-40F0-B09E-D530C8B4899BQ35910429-05B84154-334D-406F-9B10-BEB745538AFDQ36556337-0D96225C-97A2-48B1-A421-070982CD5470Q36641580-C67E7AC6-3F10-4910-9FFA-9736F1DAA1B1Q36731626-513B6211-E2B9-4616-9214-8E9737C4DA94Q36838286-46192419-3A87-4869-A820-B9AB84ABED80Q36933854-6A3F6C9A-8B28-4770-8B94-5B6334EFC3C1Q37106685-FD097E09-5CC3-46CF-81FD-0FC0E2B4BAB3Q37241938-F1EC507E-8AA9-4C2C-A654-50AA6294D93FQ37242352-C6A7742A-F4A1-4FEE-9431-DE2749D91C57Q37271252-25003F09-2C53-4079-A05B-E0E9AD18033EQ38308383-409DAC1C-6FE6-4BA5-923A-25230AA1E1AAQ38320967-45A82FF0-10C8-409D-8048-ACBFF8B16523Q38325827-5A9FB035-64F8-4D36-B8A7-FA90100406A3Q38338794-AC523109-9628-4440-A00A-0F7A66E7BFEAQ38347572-6EA007C6-36F1-4B8F-B115-5C5B1A91C291Q38885956-FB0BFF7A-9E45-4C2E-94D7-B4A7F3F0DE75Q40289987-33EA4F20-707E-443F-94C2-AAD1764FF344Q40330021-88FFE67B-495F-4950-A85C-4C5EB66802DFQ40671125-6E9D411C-F334-4082-A08F-6669D8D83895Q41324853-A8D5EB93-0034-4C07-83A5-AE5BDFBA40B7Q41994681-E968671C-AE32-4A30-B3CB-153A64360309Q42174781-F2B56182-FEFC-49EB-8B11-5265D7E4BE1CQ42515389-8CE11450-B8F4-4275-AB0A-72F01A7F10E7Q42797804-11EC52F4-98FF-4474-8EC9-D1FED5A9B196Q43052738-AE5DD1BF-41FF-465D-8FE3-00FF8582C9EFQ43435300-97CCD14F-0B95-4D02-A8A6-644EE9011AA1Q44295528-CB72D8BE-E44B-4E61-ACF9-96C4E63412A2Q44391131-EB83F6C5-15E6-4B04-A534-0475A93A14FF
P2860
Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight.
description
2000 nî lūn-bûn
@nan
2000 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Fenofibrate and rosiglitazone ...... posing effects on body weight.
@ast
Fenofibrate and rosiglitazone ...... posing effects on body weight.
@en
type
label
Fenofibrate and rosiglitazone ...... posing effects on body weight.
@ast
Fenofibrate and rosiglitazone ...... posing effects on body weight.
@en
prefLabel
Fenofibrate and rosiglitazone ...... posing effects on body weight.
@ast
Fenofibrate and rosiglitazone ...... posing effects on body weight.
@en
P2093
P356
P1476
Fenofibrate and rosiglitazone ...... posing effects on body weight.
@en
P2093
P304
P356
10.1006/BBRC.2000.2647
P407
P577
2000-05-01T00:00:00Z